- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02921724
Participatory Research for Fine-tuning of a 2.0 System to Optimise Home Management of Oral Cancer Therapies.
This is a prospective testing-validation, interventional, non-pharmacological study on a new app for oral anticancer therapy management.
A total of 80 patients will be considered: 20 evaluable patients in the training step; 60 patients in the validation step. In the training step will be considered evaluable the patients with: at least 6 weeks of treatment; visit at 6 weeks after the start of treatment performed and questionnaires self-administered.
Patients will be visited every 6 weeks. In the training step, patients will remain under observation for a minimum of 6 weeks, until change of therapy (due to progression of disease, unacceptable toxicity, death, discontinuation) or for a maximum of 12 weeks. Patients enrolled in the validation step will remain under observation until change of therapy (due to progression of disease, unacceptable toxicity, death, discontinuation) or for a maximum of 24 weeks.
The objective of this study is to assess the capability of a newly developed interactive health care application to support patients and health professionals in the shared management of oral anticancer therapies, improving adherence, preventing complications at home, toxicities, improper treatment reductions or interruptions, emergency accesses and to assess the system usability and acceptability by patients and health professionals, integration in the hospital workflow, monitoring over time patient perceived levels of quality of care, quality of life, social support, anxiety, and self-care capability.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is a prospective, interventional, non pharmacological study for testing-validation of a new app for optimising home management of oral therapies for cancer treatment.
All patients will be treated according to the local clinical practice. Enrolment period: 8 (training step) + 12 (validation step) months. Total duration of the study: 36 months. This is a multicenter study. Objective of the study is to assess the capability of a newly developed interactive health care application to support patients and health professionals in the shared management of oral anticancer therapies, and to assess the system usability and acceptability by patients and health professionals.
Eligible patients must meet the following criteria:
- adult 18-75 years old;
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1;
- candidate for treatment with capecitabine or sunitinib as monotherapy (adjuvant and advanced settings allowed);
- sufficient ability to manage mobile devices after basic training course held at baseline;
- clear understanding of the Italian language;
- written informed consent.
Health professionals and patients define the items of the system through participatory design techniques (e.g. focus group sessions, joint review).
To define whether the system is capable of monitoring patient adherence, the number of pills counted by the system (self-reported by the patient at home) will be compared with that counted by the physician as residual pills returned by the patient at the hospital visit. A difference in the number of pills within +/- 10% will be considered acceptable. A comparison of type and grade of toxicity will be made between the adverse events indicated by the system and those reported by the patient at the clinical visit. The quality of the system will be considered adequate if all the grade 3 and at least 80% of the grade 2 or more toxicity data reported by the patient at the time of the visit is recorded in the app.
To investigate system usability and acceptability, Functional Assessment of Cancer Therapy-General (FACT-G) and Hospital Anxiety and Depression Scale (HADS) questionnaires will be used. Scores will be subdivided into different subscales and analyzed using the Wilcoxon rank-sum test. Two new questionnaires have been developed and will be used to evaluate patient expectations of the system, and system acceptability + patient-doctor communication. An internationally validated questionnaire translated into Italian on system usability (SUS) will be also administered at the end of observation. Conversational interviews will be audio-recorded, transcribed and analyzed.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Bergamo, Italia, 24127
- Azienda Ospedaliera Papa Giovanni XXIII, Bergamo
-
Meldola (FC), Italia, 47014
- Irst-Irccs
-
Trento, Italia, 38123
- Azienda Provinciale per i Servizi Sanitari della Provincia Autonoma di Trento
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- ECOG-Performance Status (PS) less or equal to 1;
- life expectancy > 12 weeks;
- candidate for treatment with capecitabine or sunitinib as monotherapy (adjuvant and advanced settings allowed);
- clear understanding of the Italian language;
- subjects who are, in the opinion of the Investigator, able to understand this study, to cooperate with the study procedures and able to manage mobile devices after basic training course held at baseline;
- written informed consent
Exclusion Criteria:
- Patients receiving also intravenous anticancer treatment
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Investigación de servicios de salud
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: Cancer patients undergoing oral therapy
At the time of therapy prescription, patients candidate for oral therapy with capecitabine or sunitinib will be provided with informations on the side-effects of therapy and on the use and functions of the mobile diary app TreC-Onco.
Patients are required to manually insert data into the mobile diary app at least once a day.
Patients will be visited every 6 weeks.
During the visit, the clinician will compare adherence and toxicity data entered into the mobile diary app with those directly reported by the patient and by drug accountability.
|
TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Drug accountability comparison
Periodo de tiempo: 3 years
|
the number of pills counted by the system (self-reported by the patient at home) will be compared with that counted by the physician as residual pills returned by the patient at the hospital visit.
A difference in the number of pills within +/- 10% will be considered acceptable.
|
3 years
|
Toxicity reporting comparison
Periodo de tiempo: 3 years
|
A comparison of type and grade of toxicity will be made between the adverse events indicated by the system and those reported by the patient/detected by the doctor at the clinical visit.
The quality of the system will be considered adequate if all the grade 3 and at least 80% of the grade 2 toxicity data reported by the patient at the time of the visit is recorded in the app.
A comparison will be made between the adverse event start time reported by the system and the time of data-entry by the patient into the system.
|
3 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
System acceptability: HADS questionaire
Periodo de tiempo: 3 years
|
HADS questionaire will be analyzed using the Wilcoxon rank-sum test
|
3 years
|
System acceptability: FACT-B questionaire
Periodo de tiempo: 3 years
|
FACT-B questionaire will be analyzed using the Wilcoxon rank-sum test
|
3 years
|
System usability: system usability scale (SUS) questionaire
Periodo de tiempo: 3 years
|
system usability scale (SUS) will be analyzed using the Wilcoxon rank-sum test
|
3 years
|
System acceptability by the Q-pre questionaire
Periodo de tiempo: 3 years
|
System acceptability by the Q-pre questionaire using content and template qualitative sociological analysis
|
3 years
|
System acceptability by the Q-post questionaire
Periodo de tiempo: 3 years
|
System acceptability by the Q-post questionaire using content and template qualitative sociological analysis
|
3 years
|
System acceptability by semi-structured interviews
Periodo de tiempo: 3 years
|
System acceptability by semi-structured interviews using content and template qualitative sociological analysis
|
3 years
|
Colaboradores e Investigadores
Colaboradores
Investigadores
- Silla de estudio: Alessandro Passardi, MD, IRST IRCCS, Meldola (FC)
Publicaciones y enlaces útiles
Publicaciones Generales
- Passardi A, Foca F, Caffo O, Tondini CA, Zambelli A, Vespignani R, Bartolini G, Sullo FG, Andreis D, Dianti M, Eccher C, Piras EM, Forti S. A Remote Monitoring System to Optimize the Home Management of Oral Anticancer Therapies (ONCO-TreC): Prospective Training-Validation Trial. J Med Internet Res. 2022 Jan 26;24(1):e27349. doi: 10.2196/27349.
- Passardi A, Rizzo M, Maines F, Tondini C, Zambelli A, Vespignani R, Andreis D, Massa I, Dianti M, Forti S, Piras EM, Eccher C. Optimisation and validation of a remote monitoring system (Onco-TreC) for home-based management of oral anticancer therapies: an Italian multicentre feasibility study. BMJ Open. 2017 May 29;7(5):e014617. doi: 10.1136/bmjopen-2016-014617.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- IRST100.18
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Cáncer
-
Abramson Cancer Center of the University of PennsylvaniaTerminadoPaciente con cancerEstados Unidos
-
Peking Union Medical College HospitalTerminadoEncuesta | Estado nutricional | Paciente con cancerPorcelana
-
Ankara Medipol UniversityReclutamientoCuidados personales | Inmunoterapia | Manejo de síntomas | Paciente con cancerPavo
-
Northwestern UniversityGenzyme, a Sanofi CompanyRetiradoCANCER DE PROSTATAEstados Unidos
-
Fundacao ChampalimaudTerminado
-
University College London HospitalsTerminado
-
GenSpera, Inc.RetiradoCancer de prostata.Estados Unidos
-
University of Colorado, DenverColorado State UniversityRetiradoRealidad virtual | Diagnóstico por imagen | Educación del paciente | Paciente con cancerEstados Unidos
-
Dana-Farber Cancer InstituteTerminadoCancer de RIÑON | Cancer de prostata | Cáncer genitourinarioEstados Unidos
-
Rabin Medical CenterReclutamiento
Ensayos clínicos sobre TreC-Onco
-
Istituto Scientifico Romagnolo per lo Studio e...ReclutamientoCáncer | Tumor solido | Malignidad hematológica | Administración de Medicamentos OralesItalia
-
Azienda Provinciale per i Servizi Sanitari, Provincia...Ministero della Salute, Italy; Fondazione Bruno Kessler; Provincia Autonoma di... y otros colaboradoresReclutamiento
-
Quanta MedicalNAOS Institute of Life ScienceTerminadoSíndrome mano-pie de grado 2Francia
-
Hospices Civils de LyonAún no reclutandoNeoplasias de Cabeza y Cuello | Carcinoma de pulmón de células no pequeñas | Neoplasias colorrectalesFrancia
-
Centre Hospitalier Universitaire de Saint EtienneInstitut de Cancérologie de la Loire; Centre Antoine LacassagneTerminado
-
Cankado GmbHReclutamiento
-
Centre hospitalier de l'Université de Montréal...ReclutamientoRonquidos | Apnea del sueño | Cáncer bucal | Carcinoma de células escamosas orales | Cáncer de faringeCanadá
-
Seoul National University HospitalTerminado
-
Maxivax SAEuropean CommissionTerminadoCarcinoma de células escamosas de cabeza y cuelloSuiza